# KEYNOTE-F58 (MK-3475-F58) (NCT05482893)

> Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05482893
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Phanes Therapeutics
- Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC); Colorectal Cancer
- Interventions: Spevatamig (PT886); Paclitaxel; Gemcitabine; Abraxane; KEYTRUDA® (pembrolizumab); FOLFOX; CAPOX; FOLFIRINOX; TAS 102; Bevacizumab; Gemcitabine Combined With Cisplatin; NALIRIFOX
- Enrollment: 350
- Primary outcome: To evaluate the safety and tolerability of Spevatamig (PT886) as monotherapy and in each individual combination substudy.
- Primary outcome: To evaluate anti-tumor activity of PT886 as assessed by ORR, in Spevatamig (PT886) monotherapy and in each combination substudy.
- Primary outcome: To determine the recommended dose for expansion of Spevatamig (PT886) monotherapy.

## Indexed commentary on KEYNOTE-F58 (MK-3475-F58) so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-f58-mk-3475-f58-nct05482893